The Institute for Pharmacology and Preventive Medicine
The Institute is an experienced partner of universities, non-university institutions, health insurance companies, and pharmaceutical companies in the implementation of scientific projects in the fields of cardiovascular disease and diabetes.
Recent Activity / Publications in press
Kolwelter J, Bosch A, Jung S, Stapel L, Kennenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE. Effects of the SGLT2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Failure 2021.
McCalmont G, Durand E, Lauck S, Muir DF, Spence MS, Vasa-Nicotera M, Wood D, Saia F, Chatel N, Lüske CM, Kurucova J, Bramlage P, Frank D. Setting a Benchmark for Resource Utilization and Quality of Care in Patients undergoing Transcatheter Aortic Valve Implantation in Europe – rationale and design of the international BENCHMARK registry. Clin Cardiol 2021.
Studencan M, Pella D, Bramlage P, Kaszasova E. Clinical characteristics and management of hyperlipoproteinemia in patients with chronic coronary heart disease in Slovakia. Archives of Medical Science 2021.
PubMed listed Publications